Relmada Therapeutics Gears Up for Third Quarter Financial Call
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a pioneering biotechnology company, is poised to announce its financial results for the third quarter. The upcoming conference call on November 7, 2024, marks a significant opportunity for investors and stakeholders to catch up on the latest developments regarding the company's business progress.
Conference Call Details
The conference call and webcast are scheduled for Thursday, November 7, 2024, at 4:30 PM ET. During this session, company leaders will discuss the financial insights from the most recent quarter.
Accessing the Call
For those interested in participating, the participant dial-in number for the U.S. is 1-800-717-1738, while international participants can reach the call at 1-646-307-1865. Make sure to enter the conference ID code 60579 to join the discussion.
Replay Information
A replay will be made available on the Relmada Therapeutics website in the Investors section, allowing those unable to attend the live call to catch up on the key points discussed.
About Relmada Therapeutics
Relmada is at the forefront of developing therapeutics for diseases associated with the central nervous system (CNS), emphasizing the treatment of major depressive disorder (MDD). With an adept team dedicated to enhancing patient lives, Relmada continues to innovate in the biotech sector.
Lead Program: REL-1017
The company's flagship program, REL-1017 (esmethadone), represents a novel approach to treating MDD. As a new chemical entity (NCE), this treatment acts as an NMDA receptor (NMDAR) channel blocker, effectively targeting hyperactive channels without disrupting normal glutamatergic activity, which is essential for the body’s neurological functions.
A Focus on Major Depressive Disorder
Major depressive disorder remains a critical area of focus for Relmada Therapeutics. With REL-1017 currently in late-stage development, the company aims to provide an adjunctive treatment option for adults who struggle with this debilitating mental health condition.
Investor Relations
For inquiries, investors can reach out to Tim McCarthy from LifeSci Advisors. He is available via email at Tim@lifesciadvisors.com. Tim is well-equipped to provide more personalized insights into Relmada Therapeutics and the current investment landscape.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call will focus on discussing the recent business developments and financial results for Relmada Therapeutics for the third quarter.
How can I join the conference call?
You can join the call by dialing 1-800-717-1738 (U.S.) or 1-646-307-1865 (International) and entering the conference ID code 60579.
What can I expect to hear during the financial results call?
The call will typically provide insights into Relmada’s business performance, developments in their lead therapeutic programs, and strategic plans moving forward.
What is REL-1017 and its significance?
REL-1017 is a novel treatment option for major depressive disorder, designed to engage specific NMDA receptors in a way that maintains healthy brain function.
How can I get more information about Relmada Therapeutics?
For more information, you can visit the Relmada Therapeutics website or contact their investor relations team directly.
